Have you recently been diagnosed with Type 1 Diabetes?

The SAFEGUARD study is a clinical trial for people diagnosed with T1D in the last 100 days. The trial is testing an investigational medicine called SAB-142 which is being developed to prevent the loss of cells that produce insulin in the body.

SAB-142 is an immunoglobulin, or a human protein that may stop your immune system from attacking cells that produce your natural insulin. SAB-142 doesn’t kill immune cells but makes some cells “tired”, so they stop mistakenly attacking your own insulin-producing cells. It also helps your own cells to regulate the immune system to slow down destructive process.

SAB-142 has been developed to delay the onset and progression of T1D by decreasing the autoimmune response toward insulin producing cells in the pancreas.

SAB-142 is an investigational medicine. Investigational means the study medicine is approved for use in clinical research but not yet approved for the general treatment of people with a certain health condition.